deltatrials
Completed PHASE2 INTERVENTIONAL 3-arm NCT02296320

Study of the Efficacy and Safety of MEDI4893 (SAATELLITE)

A Phase 2 Randomised, Double-blind, Placebo-controlled, Single-dose, Dose-ranging Study of the Efficacy and Safety of MEDI4893, a Human Monoclonal Antibody Against Staphylococcus Aureus Alpha Toxin in Mechanically Ventilated Adult Subjects.

Sponsor: Antibacterial Resistance Leadership Group

Conditions Staphylococcus Aureus Pneumonia
Interventions MEDI4893 Placebo
Updated 19 times since 2017 Last updated: Dec 11, 2019 Started: Oct 10, 2014 Primary completion: Oct 2, 2018 Completion: Oct 2, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Staphylococcus Aureus Pneumonia and is currently completed. Antibacterial Resistance Leadership Group leads this study, which shows 19 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2017 · 3 months · monthly snapshot~May 2017 – ~Sep 2017 · 4 months · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Nov 2017 · 31 days · monthly snapshot~Nov 2017 – ~Dec 2017 · 30 days · monthly snapshot~Dec 2017 – ~Apr 2018 · 4 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Oct 2018 · 4 months · monthly snapshot~Oct 2018 – ~Dec 2018 · 2 months · monthly snapshot~Dec 2018 – ~Jan 2019 · 31 days · monthly snapshot~Jan 2019 – ~Nov 2019 · 10 months · monthly snapshot~Nov 2019 – ~Jan 2020 · 2 months · monthly snapshot~Jan 2020 – ~Jan 2021 · 12 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Feb 2025 · 5 months · monthly snapshot~Feb 2025 – ~Sep 2025 · 7 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

19 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE2

  2. Feb 2025 — Sep 2025 [monthly]

    Completed PHASE2

  3. Sep 2024 — Feb 2025 [monthly]

    Completed PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  5. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE2

▶ Show 14 earlier versions

  1. Jan 2020 — Jan 2021 [monthly]

    Completed PHASE2

  2. Nov 2019 — Jan 2020 [monthly]

    Completed PHASE2

  3. Jan 2019 — Nov 2019 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

  4. Dec 2018 — Jan 2019 [monthly]

    Active Not Recruiting PHASE2

  5. Oct 2018 — Dec 2018 [monthly]

    Active Not Recruiting PHASE2

  6. Jun 2018 — Oct 2018 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  7. Apr 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  8. Dec 2017 — Apr 2018 [monthly]

    Recruiting PHASE2

  9. Nov 2017 — Dec 2017 [monthly]

    Recruiting PHASE2

  10. Oct 2017 — Nov 2017 [monthly]

    Recruiting PHASE2

  11. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE2

  12. May 2017 — Sep 2017 [monthly]

    Recruiting PHASE2

  13. Feb 2017 — May 2017 [monthly]

    Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Recruiting PHASE2

    First recorded

Oct 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Antibacterial Resistance Leadership Group
  • Innovative Medicines Initiative
  • MedImmune LLC
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: MedImmune LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandroupoli, Greece , Angers, France , Arlon, Belgium , Athens, Greece , Atlanta, United States , Barcelona, Spain , Berlin, Germany , Brno, Czechia , Brussels, Belgium , Clermont-Ferrand, France and 35 more locations